This Week in Peptide Research: Retatrutide Posts Its First Phase 3 Sleep Apnea Results

Peptide Science Daily reviewed new PubMed listings for its tracked compounds from October 19 through October 25, 2026. The week's lead story was the first published phase 3 data testing an incretin peptide specifically for obstructive sleep apnea. Several further papers examined the wider multi-agonist weight-loss pipeline, two publications addressed obesity treatment in children and in patients with rare genetic forms of the disease, and two mouse studies reported protective effects of gut and mitochondrial peptides against intestinal and kidney injury.

The New England Journal of Medicine published results from TRIUMPH-1-OSA and TRIUMPH-2-OSA, two phase 3 trials testing retatrutide, Eli Lilly's investigational triple GIP, GLP-1, and glucagon receptor agonist, against placebo in adults with moderate-to-severe obstructive sleep apnea and a body mass index of at least 27. TRIUMPH-1-OSA enrolled 243 participants without type 2 diabetes and TRIUMPH-2-OSA enrolled 448 participants with it; average baseline apnea-hypopnea index (the number of breathing pauses per hour of sleep) was 58.6 and 55.9 events per hour in the two trials, and average body weight was about 120 kg and 116 kg. At 80 weeks, weekly subcutaneous retatrutide at 9 mg or 12 mg reduced the apnea-hypopnea index by 24 to 34 more events per hour than placebo in TRIUMPH-1-OSA and by 14 to 15 more events per hour than placebo in TRIUMPH-2-OSA. Body weight fell by 12 to 22 percent with retatrutide across the two trials, compared with about 5 percent with placebo. Gastrointestinal problems were the most commonly reported side effect in both trials, the study's authors wrote. The trials are registered as NCT05929066 and NCT05929079 and were funded by Eli Lilly. Retatrutide has no FDA, EMA, or TGA approval for any indication; the sleep apnea results extend its phase 3 TRIUMPH obesity and type 2 diabetes program to a new potential use rather than establishing one.

Two further papers this week placed that result in a broader pipeline context without adding new clinical trial data of their own. A narrative review in Reviews in Endocrine and Metabolic Disorders, from researchers at the Medical University of Bialystok in Poland, summarized evidence that the hormone GIP acts differently in visceral versus subcutaneous fat, promoting fat storage and inflammation in visceral fat while behaving more variably in subcutaneous fat; the authors wrote that this depot-specific biology may help explain why dual and triple incretin agonists including tirzepatide and retatrutide produce substantial weight loss. Separately, a group of Indian researchers published a computational and literature-based comparison of orforglipron, semaglutide, and tirzepatide in the journal OMICS, combining molecular modeling with previously reported trial results rather than new patient data. Drawing on the head-to-head SURMOUNT-5 trial, the paper reiterated that tirzepatide produced more weight loss than semaglutide (20.2 percent versus 13.7 percent at 72 weeks) and ranked it highest under most of the paper's own weighting schemes, while finding that orforglipron's oral absorption, despite exceeding standard small-molecule chemistry limits, gave it an advantage on manufacturing and accessibility criteria. The authors concluded that no single drug outperforms the others on every measure and that drug choice should follow what matters most to the individual patient.

Pediatric and rare-disease obesity drew attention from two publications. JAMA ran a review from University of Minnesota and Duke University physicians on obesity in children aged 2 to 12, reporting that the condition affects 15 percent of US children aged 2 to 5 and 22 percent of those aged 6 to 11. The review noted that setmelanotide, a melanocortin-4 receptor agonist, is currently the only obesity drug the FDA has approved for children younger than 12, covering three rare monogenic obesity conditions (variants in the LEPR, POMC, and PCSK1 genes), Bardet-Biedl syndrome, and acquired hypothalamic obesity; it also cited a randomized trial in which liraglutide reduced body mass index by 7.4 percent in children aged 6 to under 12, an age group for which liraglutide is not currently FDA-approved (liraglutide is approved for ages 12 and older). Separately, in the Journal of Clinical Endocrinology and Metabolism, a multi-center team led by researchers at the University of Ulm analyzed metabolic outcomes in 18 of the 21 patients from setmelanotide's original phase 3 trials for POMC and leptin-receptor (LEPR) deficiency obesity. After roughly a year of treatment, a composite score of metabolic syndrome severity based on body mass index fell on average, with significantly larger improvements in patients who lost more weight and in those with POMC deficiency compared with LEPR deficiency. Setmelanotide, sold as Imcivree, is FDA-approved for these indications; the analysis reports metabolic outcomes within that approved use rather than a new one.

Two mouse studies this week examined how peptides protect specific organs from injury. In Cell Reports Medicine, a team led by Daniel Drucker at the University of Toronto's Lunenfeld-Tanenbaum Research Institute reported that mice engineered to lack GLP-1 or GLP-2 receptors, or to lack gut production of the proglucagon gene that gives rise to both hormones, suffered more intestinal damage after their immune T cells were activated to attack the gut. Treating the gut-proglucagon-deficient mice with teduglutide (a GLP-2 receptor agonist), semaglutide (a GLP-1 receptor agonist), or both together reduced that immune-driven intestinal damage, pointing to a protective role for both hormone pathways beyond their established uses in short bowel syndrome and diabetes or obesity. Separately, in Biochemical Pharmacology, a Chinese team at Central South University reported that MOTS-c, a mitochondrial-derived peptide with no approved therapeutic use that is classified as prohibited in sport by the World Anti-Doping Agency, reduced kidney tubule injury, lipid buildup, and cell senescence markers in diabetic mice, an effect the authors tied to a specific protein, LARS1, that normally blocks the cell's lipid-clearing process. Both studies are preclinical, conducted in mice, and have not been tested in humans.

This week's coverage ran from the first phase 3 test of an incretin peptide in sleep apnea to pipeline-positioning research on established weight-loss drugs, metabolic data from an already-approved rare-obesity therapy, and two mouse studies probing gut and kidney protection. Orforglipron, semaglutide, tirzepatide, setmelanotide, teduglutide, and liraglutide are each approved for at least one indication in at least one jurisdiction; retatrutide remains investigational with no FDA, EMA, or TGA approval for any use; MOTS-c has no approved therapeutic use anywhere and is prohibited in sport. As with all research covered here, these are findings each study or review reported, not established clinical fact or treatment guidance.